N- Acetylcysteine in Airway Clearance in Bronchiectasis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT07293884
- Record updated
- 30 October 2026
- Original description
It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis. Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity.Read full original descriptionShow less
Efficacy of Nebulized Versus Intravenous N- Acetylcysteine in Airway Clearance in Bronchiectasis
It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis. Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity.
Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis
Inclusion: Adults aged 18 years or older; Clinical and high-resolution CT diagnosis of non-cystic fibrosis bronchiectasis; Hospital admission due to an acute exacerbation of bronchiectasis.
Exclusion: Traction bronchiectasis secondary to interstitial lung disease; Active pulmonary tuberculosis; Known hypersensitivity to N-acetylcysteine (NAC); Primary diagnosis of chronic obstructive pulmonary disease (COPD); Cystic fibrosis; Massive hemoptysis; Pregnancy or lactation; Primary diagnosis of bronchial asthma; Immediate indication for invasive mechanical ventilation; Inability to provide informed consent or reliably complete symptom assessments; Absence of baseline expectoration difficulty (score 0 on the four-point scale); Transient bronchial dilatation secondary to acute consolidation or atelectasis; Uncertain diagnosis of permanent bronchiectasis.